Date: 2012-11-26
Type of information: Fundraising
Company: TxCell (France)
Investors: InnoBio (France) Auriga Partners (France) Seventure Partners (France)
Amount: €12.4 million
Funding type: financing round
Planned used: These additional financial resources will enable TxCell to pursue the development of its lead product candidate, Ovasave®. Ovasave® is an antigen-specific Treg cell-based immunotherapy for the treatment of Crohn’s disease in patients who are refractory to current treatments. To date, TxCell has completed a first in man PhI/II clinical study carried out in France to evaluate the tolerability and efficacy of Ovasave®. The results showed good tolerance and a positive efficacy signal. This was particularly impressive in the best dose group with 75% of patients treated responding. The study results have just been published in Gastroenterology (Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn\'s Disease”, Pierre Desreumaux, et al, 2012, Nov., Volume 143, Issue 5, 1207-1217.e2). These promising results meant that TxCell decided to pursue the clinical development of Ovasave® in the same patient population by performing a larger international blinded and placebo controlled phase IIb study.
Others: TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, has raised €12.4 million in a third financing round. This additional capital was provided by the InnoBio fund, managed by CDC Entreprises, for €6 million and by TxCell’s existing shareholders Auriga Partners and Seventure Partners.
Therapeutic area: Autoimmune diseases - Inflammatory diseases
